Sheffield Bio-Science to distribute Wockhardt's recombinant insulin to cell culture market

22 February 2011

India’s Wockhardt (BSE: WOCK) says that it has formed a strategic alliance with Sheffield Bio-Science, a subsidiary of USA-based Kerry Group, which will become the exclusive global sales and distribution partner for its recombinant insulin. According to estimates, the potential in cell culture markets is around $50 million.

Commenting on the alliance, Habil Khorakiwala, chairman of Wockhardt, stated: "This partnership is a reaffirmation of Wockhardt's biotechnology research prowess and a confluence of innovative novel technology now being offered to global cell culture markets."

Wockhardt says it was the first in Asia and only the fourth company in the world to have developed, manufactured and marketed Wosulin - recombinant insulin injectables. Wockhardt's state-of-the-art Biotech Park in Aurangabad has six dedicated manufacturing facilities.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK